The company is well-positioned to continue gaining momentum against Novo in weight loss while simultaneously leading the ...

Lilly and Novo still dominate the market for weight-loss and diabetes drugs, but the race is heating up in more ways than one ...

Eli Lilly (LLY -1.28%) and Novo Nordisk (NVO 1.03%) have competed for decades. They're both leaders in the areas of insulin ...

Pharmaceutical giant Eli Lilly (NYSE: LLY) is having a moment right now. Over the last two years the company has made a ...

Since pharmaceutical giant Eli Lilly (NYSE: LLY) reported earnings for the third quarter on Oct. 30, shares have been ...

Eli Lilly's key products, Mounjaro and Zepbound, dominate the U.S. weight loss market. Read more to see why I rate LLY stock ...

Eli Lilly and Company (NYSE:LLY – Get Free Report) was downgraded by research analysts at StockNews.com from a “buy” rating ...

GlobalData tracks drug-specific phase transition and likelihood of approval scores, in addition to indication benchmarks based off 18 years of historical drug development data. Attributes of the drug, ...

Shares of Danish pharmaceutical giant Novo Nordisk plummeted more than 22% on Friday after reporting results in a late-stage ...

The pharmaceutical industry faces significant challenges as Novo Nordisk and Eli Lilly grapple with trial setbacks and market ...

GlobalData analysis sees Lilly's investment in UK life sciences as an opportunity to drive economic growth whilst improving public health.

Eli Lilly (NYSE: LLY) and Novo Nordisk (NYSE ... are the stars of the show, the pharmaceutical giant has several other medicines whose sales are growing fast. In the third quarter, Lilly's ...